Myosteatosis and bone marrow adiposity are not associated among postmenopausal women with fragility fractures.
MRI
bone marrow adiposity
bone-fat interactions
bone-muscle interactions
menopause
myosteatosis
osteoporosis
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
03
2023
accepted:
23
05
2023
medline:
7
7
2023
pubmed:
5
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
Although paravertebral intramuscular fatty infiltration (known as myosteatosis) following a vertebral fracture is well-known, scarce data are available regarding interactions between muscle, bone, and other fat depots. Based on a homogeneous cohort comprising postmenopausal women with or without a history of fragility fracture, we aimed to better depict the interrelationship between myosteatosis and bone marrow adiposity (BMA). 102 postmenopausal women were included, 56 of whom had a fragility fracture. Mean proton density fat fraction (PDFF) was measured in the psoas (PDFF PDFF in the psoas and paravertebral muscles was higher in the fracture group compared to controls even after adjustment for age, weight, and height (PDFF Myosteatosis is not associated with BMA among postmenopausal women with fragility fractures. Whereas myosteatosis was associated with other fat depots, BMA appears uniquely regulated.
Identifiants
pubmed: 37404309
doi: 10.3389/fendo.2023.1178464
pmc: PMC10316646
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1178464Informations de copyright
Copyright © 2023 Badr, Dapvril, Lombardo, Khizindar, Martin, Cortet, Cotten and Paccou.
Déclaration de conflit d'intérêts
JP has received honoraria from Amgen, MSD, Eli Lilly, and Pfizer. BC has received honoraria from Amgen, Eli Lilly, Expanscience, Ferring, Medtronic, Novartis, Nordic, Roche Diagnostics, and Theramex. AC has received honoraria from Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Musculoskelet Disord. 2018 May 7;19(1):135
pubmed: 29734942
Ageing Res Rev. 2014 May;15:51-60
pubmed: 24632496
Obesity (Silver Spring). 2011 Jan;19(1):49-53
pubmed: 20467419
Exp Gerontol. 2020 May;133:110856
pubmed: 32006635
Front Physiol. 2020 Aug 07;11:963
pubmed: 32903666
Diabetes Metab J. 2021 Jul;45(4):482-491
pubmed: 34352985
J Neuromuscul Dis. 2016 Mar 3;3(1):1-28
pubmed: 27854210
Diabetes. 2021 Nov;70(11):2457-2467
pubmed: 34711670
Quant Imaging Med Surg. 2020 Jan;10(1):128-136
pubmed: 31956536
J Clin Endocrinol Metab. 2023 Apr 05;:
pubmed: 37017011
Obesity (Silver Spring). 2013 Oct;21(10):2118-25
pubmed: 23408772
Quant Imaging Med Surg. 2018 Feb;8(1):60-85
pubmed: 29541624
Curr Osteoporos Rep. 2020 Aug;18(4):408-421
pubmed: 32519283
Eur Radiol. 2022 Sep;32(9):6504-6513
pubmed: 35380225
AJNR Am J Neuroradiol. 2001 Sep;22(8):1620-7
pubmed: 11559519
J Bone Miner Res. 2020 Mar;35(3):516-527
pubmed: 31675452
Aging Clin Exp Res. 2022 Sep;34(9):2089-2098
pubmed: 35633478
Sci Rep. 2020 Jun 16;10(1):9686
pubmed: 32546722
J Magn Reson Imaging. 2005 Aug;22(2):279-85
pubmed: 16028245
Eur J Phys Rehabil Med. 2013 Feb;49(1):111-7
pubmed: 23575205
Front Physiol. 2017 Feb 15;8:87
pubmed: 28261109
Osteoporos Int. 2020 Jun;31(6):1089-1095
pubmed: 32060561
Magn Reson Med. 2011 Nov;66(5):1312-26
pubmed: 21452279
J Clin Endocrinol Metab. 2009 Jun;94(6):2129-36
pubmed: 19318450
J Clin Endocrinol Metab. 2013 Jun;98(6):2294-300
pubmed: 23553860
Curr Osteoporos Rep. 2020 Aug;18(4):388-400
pubmed: 32529456
Bone. 2019 Jan;118:8-15
pubmed: 29477645
J Bone Miner Res. 2020 Feb;35(2):326-332
pubmed: 31618468
Biogerontology. 2001;2(3):165-71
pubmed: 11708718
J Magn Reson Imaging. 2021 Jul;54(1):12-35
pubmed: 32584496